Vanessa K. Pazdernik, MS

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota

  • 2Articles
  • 2025Active
  • 5Collaborators
  • 4Citations

About

Vanessa K. Pazdernik, MS is affiliated with Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota. Vanessa K. Pazdernik has authored or co-authored 2 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders in 2025. Their work focuses on Depression (MDD) and Suicide.

Publications

JCP
Ketamine Reduces Suicidality Associated ED Use in Patients With Treatment-Resistant Depression
Original Research

Ketamine Reduces Suicidality Associated ED Use in Patients With Treatment-Resistant Depression

September 17, 2025

After the acute phase of ketamine treatment, ED visits for suicidal ideation decreased by 84%, and total ED visits for suicidality decreased by 63%.
, , , et al
JCP
Long-Term Outcomes of IV Ketamine and IN Esketamine in Treatment-Refractory Depression
Original Research

Long-Term Outcomes of IV Ketamine and IN Esketamine in Treatment-Refractory Depression

July 30, 2025

The study results suggest that patients with treatment-resistant depression who are on maintenance treatment require less frequent treatments with IV ketamine compared to IN esketamine.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe